OptiBiotix Health PLC Distribution agreement for SlimBiome

TIDMOPTI

OptiBiotix Health PLC

28 November 2023

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

Distribution agreement with Ravenswood for SlimBiome(R)

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, announces it has signed an agreement with Ravenswood Ingredients Pty Ltd ("Ravenswood") for the distribution of SlimBiome (R) in Australia and New Zealand.

Ravenswood is part of the Brenntag group, a specialised ingredient supplier with more than 17,000 employees in over 72 countries, and revenues of EUR19.4bn in 2022. Brenntag group acquired Ravenswood in November 2022 as part of its nutrition strategy which focuses on specialised value-added ingredients. See: Brenntag strengthens its position in Specialties in Australia and New Zealand by acquiring the Life Science business from Ravenswood | Brenntag .

Ravenswood brings access to the food and beverage markets and will complement existing partner capabilities which are largely focused on the meal replacement market to broaden OptiBiotix's impact in Australia and New Zealand. This is part of a strategy of building partnerships to support expansion of OptiBiotix's geographical footprint with companies who bring national and international capability for highly differentiated value-added ingredients in high growth markets around the world.

S tep hen O'Ha r a, CEO of O pti B i oti x, c o mmented : "We are pleased to announce this agreement with Ravenswood who bring specialised food ingredient expertise as part of the Brenntag group, a global market leader in chemicals and ingredients distribution. This agreement is another example of OptiBiotix working with large partners and extends access to the food and beverage markets within Australia and New Zealand with a company which is part of a group which is a global leader in the ingredients market."

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                           www.optibiotix.com 
 Neil Davidson, Chairman                 Contact via Walbrook below 
 Stephen O'Hara, Chief Executive 
 
 Peterhouse Capital Limited (Broker)             Tel: [phone] 
 Duncan Vasey / Lucy Williams 
 
 Walbrook PR Ltd                                 Mob: [phone] 
 Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFEMFWWEDSEEF

(END) Dow Jones Newswires

November 28, 2023 02:00 ET (07:00 GMT)